NCT03300882 (PREDICT CMV) is a clinical trial of Procedure in Lung Transplant, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Who is sponsoring NCT03300882?

NCT03300882 is sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

What drugs are being tested in NCT03300882?

Interventions in NCT03300882: Procedure.

What condition does NCT03300882 study?

NCT03300882 studies Lung Transplant.

Is NCT03300882 still recruiting?

NCT03300882 is currently completed. Last updated 6 August 2020.

Last reviewed 2020-08-06 · How we verify

NCT03300882: PREDICT CMV

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PREDICT Cytomegalovirus (CMV)

Completed Last updated 6 August 2020

What this trial tests

trial testing Procedure in Lung Transplant in 84 participants. Completed in 25 November 2019.

Timeline

31 October 2017

Primary endpoint
25 November 2019

25 November 2019

Quick facts

Lead sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Status	Completed
Study type	OBSERVATIONAL
Enrollment	84
Start date	31 October 2017
Primary completion	25 November 2019
Estimated completion	25 November 2019
Sites	4 locations across Canada, United States

Drugs / interventions tested

Procedure

Conditions studied

Lung Transplant — all drugs for Lung Transplant →

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Who can join

18 and older, any sex, with Lung Transplant. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall objective of this study is to establish a personalized test to measure individualized cytomegalovirus (CMV) specific immunity in lung transplant recipients in an effort to guide antiviral prophylaxis duration in clinical practice. Targeted participants are those: * enrolled in clinical research study CTOT-20 (Clinical Trials.gov ID: NCT02631720) who * are CMV recipient positive by serology as determined using methods in accordance with current local organ procurement organization policies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Procedure

Trials testing the same drug.

NCT04096755 — Targeted Metabolic Profiling in Deep Vein Thrombosis · unknown
NCT03624738 — Femorofemoral Bypass in Redo Cardiac Surgery · NA · unknown
NCT03309436 — Effects of Clomiphene Citrate Ovulation Induction on Frozen Embryo Transfer · Phase 4 · unknown
NCT03135600 — The Influence of Running to ACL Deficiency · NA · completed
NCT03135613 — Kinematics of Knees of Patients With Tumor Around Knee After Microwave Ablation With Plate Internal Fixation · NA · unknown

Other recruiting trials for Lung Transplant

Currently open trials in the same condition.

NCT07035743 — Bronchial Response to Exercise After Double Lung Transplantation · recruiting
NCT06476132 — Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients · Phase 2 · recruiting
NCT06033196 — Tocilizumab in Lung Transplantation · Phase 2 · recruiting
NCT05924113 — A Study of Latin Dance for Post- Lung Transplant · NA · recruiting
NCT05898776 — 10°C vs 4°C Lung Preservation RCT · NA · active not recruiting

Other National Institute of Allergy and Infectious Diseases (NIAID) trials

Trials by the same sponsor.

NCT07216794 — Small Trial of Alendronate Impact on the Reservoir of HIV · Phase 2 · not yet recruiting
NCT07215858 — BPL-1357 Against H1N1 Influenza Virus Challenge · Phase 2 · recruiting
NCT06987318 — A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) · Phase 1 · not yet recruiting
NCT07124559 — A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of · Phase 1, PHASE2 · not yet recruiting
NCT07342491 — Dasatinib for HIV-1 Reservoir Reduction · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03300882 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Institute of Allergy and Infectious Diseases (NIAID)
Last refreshed: 6 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03300882.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing